ASND

Ascendis Pharma A/S Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ascendispharma.com
Employees(FY) 797
ISIN US04351P1012

Performance

-3.49%

-10.77%

-4.91%

-8.33%

-0.14%

YTD

+33.22%

Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Advanced Technical Analysis

Technical Analysis of ASND 2024-11-04

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 30 reinforcing the bearish outlook. This combination signals caution for potential investors as the market appears to be struggling to g...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ASND

Stock Rank

Recent News & Updates

2024-11-05 07:10
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform(TipRanks)
2024-11-04 18:27
Ascendis Pharma and Novo Nordisk Join Forces(Yahoo Finance)
2024-11-04 15:30
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug(Quartz)
2024-11-04 13:34
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug(Benzinga)
2024-11-04 11:01
Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases(MT Newswires)
2024-11-04 07:00
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases(GlobeNewswire)
2024-11-03 18:00
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases(Globenewswire)
2024-10-01 10:13
Ascendis Pharma submits sBLA for growth hormone deficiency therapy(Pharmaceutical Technology)
2024-10-01 06:04
High Growth Tech Stocks To Watch In October 2024(Simply Wall St.)
2024-09-30 09:23
Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug(MT Newswires)
2024-09-30 08:30
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency(GlobeNewswire)
2024-09-30 08:30
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024(GlobeNewswire)
2024-09-29 20:30
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency(Globenewswire)
2024-09-29 20:30
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 2024(Globenewswire)
2024-09-25 15:50
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish(Benzinga)
2024-09-20 09:28
Sector Update: Health Care Stocks Rise Premarket Friday(MT Newswires)
2024-09-20 04:08
Ascendis Pharma Prices Offering of American Depositary Shares(MT Newswires)
2024-09-19 20:16
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs(GlobeNewswire)
2024-09-19 08:16
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs(Globenewswire)
2024-09-18 16:38
Ascendis Pharma Unveils $300 Million ADS Offering(MT Newswires)
2024-09-18 16:04
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs(GlobeNewswire)
2024-09-18 04:04
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs(Globenewswire)
2024-09-17 14:12
Ascendis Soars on Encouraging Data From Dwarfism Drug Study(Zacks)
2024-09-17 09:02
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?(Zacks)
2024-09-17 01:30
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares(GuruFocus.com)
2024-09-16 16:01
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug(Investor's Business Daily)
2024-09-16 15:12
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term(Benzinga)
2024-09-16 10:06
Ascendis Pharma Says Trial of Potential Dwarfism Drug Achieved Primary Endpoint(MT Newswires)
2024-09-16 07:00
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo(GlobeNewswire)
2024-09-15 19:00
Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo(Globenewswire)

Page 1 of 9

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.